JP2016505039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505039A5 JP2016505039A5 JP2015553775A JP2015553775A JP2016505039A5 JP 2016505039 A5 JP2016505039 A5 JP 2016505039A5 JP 2015553775 A JP2015553775 A JP 2015553775A JP 2015553775 A JP2015553775 A JP 2015553775A JP 2016505039 A5 JP2016505039 A5 JP 2016505039A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- metformin
- glp1r agonist
- glp1r
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753567P | 2013-01-17 | 2013-01-17 | |
| US61/753,567 | 2013-01-17 | ||
| PCT/US2014/011394 WO2014113357A1 (en) | 2013-01-17 | 2014-01-14 | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505039A JP2016505039A (ja) | 2016-02-18 |
| JP2016505039A5 true JP2016505039A5 (enExample) | 2017-02-16 |
| JP6445459B2 JP6445459B2 (ja) | 2018-12-26 |
Family
ID=50030537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553775A Active JP6445459B2 (ja) | 2013-01-17 | 2014-01-14 | Ｇｌｐ１ｒアゴニストとメトホルミンの組合わせおよび２型糖尿病その他の障害の処置のためのその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150313908A1 (enExample) |
| EP (1) | EP2945618B1 (enExample) |
| JP (1) | JP6445459B2 (enExample) |
| KR (1) | KR102165434B1 (enExample) |
| CN (1) | CN104968341B (enExample) |
| AU (1) | AU2014207748B2 (enExample) |
| CA (1) | CA2896308C (enExample) |
| EA (1) | EA201591123A1 (enExample) |
| ES (1) | ES2687083T3 (enExample) |
| IL (1) | IL239714A0 (enExample) |
| MX (1) | MX366685B (enExample) |
| SG (2) | SG11201504778UA (enExample) |
| WO (1) | WO2014113357A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019060653A1 (en) | 2017-09-22 | 2019-03-28 | Regeneron Pharmaceuticals, Inc. | GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF |
| KR20210005843A (ko) * | 2018-05-08 | 2021-01-15 | 브이티브이 테라퓨틱스 엘엘씨 | Glp1r 작용제의 치료적 용도 |
| JP2023528565A (ja) * | 2020-04-01 | 2023-07-05 | ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． | Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法 |
| WO2021196951A1 (zh) * | 2020-04-01 | 2021-10-07 | 杭州中美华东制药有限公司 | Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法 |
| JP7728872B2 (ja) * | 2020-12-31 | 2025-08-25 | ドン・クク・ファーム・カンパニー・リミテッド | 新規な溶出率を示すタダラフィルまたはこの薬学的に許容される塩及びデュタステリドまたはこの薬学的に許容される塩を含む医薬組成物 |
| KR20250075642A (ko) | 2022-09-21 | 2025-05-28 | 리제너론 파아마슈티컬스, 인크. | 비만, 당뇨병 및 간 기능 장애를 치료하는 방법 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080472A (en) | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
| US20090221652A1 (en) * | 2005-11-07 | 2009-09-03 | Geesaman Bard J | Combinations of metformin and meglitinide |
| EP2262364B1 (en) | 2008-03-07 | 2016-03-02 | vTv Therapeutics LLC | Oxadiazoanthracene compounds for the treatment of diabetes |
| MX2011010347A (es) * | 2009-03-30 | 2011-11-29 | Transtech Pharma Inc | Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos. |
| US20110064806A1 (en) | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| PT2554183T (pt) * | 2009-11-13 | 2018-07-09 | Sanofi Aventis Deutschland | Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina |
| US20130040878A1 (en) * | 2011-05-13 | 2013-02-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in the treatment of diabetes type 2 patients |
-
2014
- 2014-01-14 MX MX2015008555A patent/MX366685B/es active IP Right Grant
- 2014-01-14 SG SG11201504778UA patent/SG11201504778UA/en unknown
- 2014-01-14 JP JP2015553775A patent/JP6445459B2/ja active Active
- 2014-01-14 SG SG10201704716XA patent/SG10201704716XA/en unknown
- 2014-01-14 KR KR1020157018661A patent/KR102165434B1/ko active Active
- 2014-01-14 CA CA2896308A patent/CA2896308C/en active Active
- 2014-01-14 EP EP14702159.6A patent/EP2945618B1/en active Active
- 2014-01-14 ES ES14702159.6T patent/ES2687083T3/es active Active
- 2014-01-14 CN CN201480004613.0A patent/CN104968341B/zh active Active
- 2014-01-14 WO PCT/US2014/011394 patent/WO2014113357A1/en not_active Ceased
- 2014-01-14 EA EA201591123A patent/EA201591123A1/ru unknown
- 2014-01-14 AU AU2014207748A patent/AU2014207748B2/en active Active
-
2015
- 2015-06-30 IL IL239714A patent/IL239714A0/en unknown
- 2015-07-14 US US14/799,222 patent/US20150313908A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505039A5 (enExample) | ||
| AU2012330885B2 (en) | Oral immediate release formulations for substituted quinazolinones | |
| TWI329014B (en) | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3receptor antagonist/inverse agonist | |
| JP2014528474A5 (enExample) | ||
| JP2019517542A5 (enExample) | ||
| JP2009542699A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| WO2009127974A3 (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
| JP6445459B2 (ja) | Ｇｌｐ１ｒアゴニストとメトホルミンの組合わせおよび２型糖尿病その他の障害の処置のためのその使用 | |
| JP2022031813A (ja) | １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| JP2020529440A5 (enExample) | ||
| JP2012502103A5 (enExample) | ||
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| TWI606848B (zh) | 包含格米列汀與美氟明的組合藥物及其製備方法 | |
| JP2014511365A5 (enExample) | ||
| JP2018500297A (ja) | 脂肪代謝の調節に供する医薬品の製造のための第一鉄アミノ酸キレートを含む組成物の使用 | |
| JP2019528290A5 (enExample) | ||
| JP2009506043A5 (enExample) | ||
| JP2020536068A5 (enExample) | ||
| TW200922546A (en) | Galenical formulations of organic compounds | |
| EP3796901A2 (en) | Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease | |
| Harano et al. | Proposal of Inappropriate Insulin Syndrome Screened with Standard Cookie Meal, A Possible Accelerating and Common Factor for Corona 19, Metabolic Syndrome and Obesity and its Clinical Significance | |
| JP2019529554A5 (enExample) | ||
| JP2012224589A (ja) | 糖質吸収抑制物質 | |
| WO2024231312A2 (en) | Combination therapy |